A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Hu5F9 G4 (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Forty Seven
  • Most Recent Events

    • 31 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
    • 05 Jun 2018 Initial phase 1b/2 results (n=22) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2018 Results presented in a Forty Seven media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top